We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of novobiocin on the viability of human gingival fibroblasts (HGF-1).
- Authors
Szkaradkiewicz, Anna K.; Karpi¿ski, Tomasz M.; Szkaradkiewicz, Andrzej
- Abstract
Background: Novobiocin is a coumarin antibiotic, which affects also eukaryotic cells inhibiting activity of Heat shock protein 90 (Hsp90). The Hsp90 represents a molecular chaperone critical for stabilization and activation of many proteins, particularly oncoproteins that drive cancer progression. Currently, Hsp90 inhibitors focus a significant attention since they form a potentially new class of drugs in therapy of cancer. However, in the process of tumorigenesis a significant role is played also by the microenvironment of the tumour, and, in particular, by cancer-associated fibroblasts (CAFs). This study aimed at examination of the effect played by novobiocin on viability of human gingival fibroblasts (HGF-1). Methods: The studies were conducted using 24 h cultures of human gingival fibroblasts - HGF-1 (CRL-2014) in Chamber Slides, in presence of 0.1, 0.5, 1.0, 2.5 or 5.0 mM novobiocin. Cell viability was evaluated using fluorescence test, ATP assay and LDH release. Results: Viability of HGF-1 was drastically reduced after 5 hour treatment with novobiocin in concentrations of 1 mM or higher. In turn, the percentage of LDH-releasing cells after 5 h did not differ from control value although it significantly increased after 10 h incubation with 1 mM and continued to increase till the 20th hour. Conclusions: The obtained data indicate that novobiocin may induce death of human gingival fibroblasts. Therefore, application of the Hsp90 inhibitor in neoplastic therapy seems controversial: on one hand novobiocin reduces tumour-associated CAFs but, on the other, it may induce a significant destruction of periodontium.
- Subjects
NOVOBIOCIN; EUKARYOTIC cells; HEAT shock proteins; CANCER invasiveness; FIBROBLASTS; CANCER treatment; DRUG efficacy; CANCER
- Publication
BMC Pharmacology & Toxicology, 2014, Vol 15, Issue 1, p1
- ISSN
2050-6511
- Publication type
Article
- DOI
10.1186/2050-6511-15-25